NCT06406153 - Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 10, 2022

Primary Completion Date

August 12, 2023

Study Completion Date

November 18, 2023

Conditions

Mucopolysaccharidosis Type 1

Interventions

BIOLOGICAL

Laronidase

Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.

DRUG

Antihistamine

An antihistamine is administered one hour before the infusion.

DRUG

Antipyretic

An antipyretic is administered one hour before the infusion.

Trial Locations (4)

Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad

Growth and Development Research Center, Childrens Medical Center, Tehran

Loghman Hospital, Tehran

Mofid Childrens Hospital, Tehran